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Summary. In this overview we address the three phase III
studies that compared new oral anticoagulants (dabigatran,
rivaroxabanandapixaban)withwarfarin in the settingof stroke
prevention in atrial ﬁbrillation. Strengths andweaknesses of the
studies were examined in detail through indirect comparison.
We analyze and comment the inclusion and exclusion criteria,
the characteristics of randomized patients, the primary eﬃcacy
and safety end points and side eﬀects. All new oral anticoag-
ulants resulted in being non-inferior to vitaminKantagonists in
reducing stroke or systemic embolism in patients with atrial
ﬁbrillation. Dabigatran 150 mg and apixaban were superior to
vitamin K antagonists. Importantly, new oral anticoagulants
signiﬁcantly reduced hemorrhagic stroke in all three studies.
Major diﬀerences among new oral anticoagulants include the
way they are eliminated and side eﬀects. Both dabigatran and
apixaban were tested in low- to moderate-risk patients (mean
CHADS2 [Congestive heart failure, Hypertension, Age, Dia-
betes, Stroke] score = 2.1–2.2) whereas rivaroxabanwas tested
in high-risk patients (mean CHADS2 score = 3.48) and at
variance with dabigatran and apixaban was administered once
daily. Apixaban signiﬁcantly reducedmortality from any cause.
The choice of a neworal anticoagulant should take into account
these and other diﬀerences between the new drugs.
Keywords: anticoagulants, apixaban, atrial, dabigatran, ﬁbril-
lation, rivaroxaban.
Introduction
Three novel oral anticoagulants (NOA), dabigatran, rivarox-
aban and apixaban, have been tested vs. vitamin K
antagonists (VKA) for stroke prevention in non-valvular
atrial ﬁbrillation (AF) [1–3]. NOA have potential advantages
as compared with VKA [4]: (i) a rapid onset of action
without the need for bridging therapy; (ii) a predictable
anticoagulant effect without the need for dose-adjustment
laboratory testing; and (iii) low food–drug interactions
without the need for restrictions. Table 1 illustrates the
characteristics of dabigatran, rivaroxaban and apixaban.
Dabigatran etexilate is a prodrug that is rapidly converted
into the active compound dabigatran by esterases. Dabiga-
tran reversibly inhibits the active site of thrombin (IIa).
Rivaroxaban and apixaban are direct factor (F)Xa inhibitors.
The time to a maximal drug concentration in plasma after
oral administration of each of the three NOA is short (1–3 h)
and the pharmacokinetics is linear except for rivaroxaban.
Dabigatran possesses a lower bioavailability (7%) and
protein binding (35%) compared with the other NOA. The
plasma half-lives are similar for the three drugs ranging from
8 to 15 h. Dabigatran is excreted unchanged by the kidneys
(80%) and likewise rivaroxaban and apixaban are a
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substrate of the P-glycoprotein (P-gp) transporter. One-third
of rivaroxaban is cleared unchanged via the kidneys and the
remaining two-thirds are metabolized by the liver via
CYP3A4/CYP3A5 and CYP2J2-dependent or independent
pathways (one-third each, respectively). Apixaban which has
predominant non-renal clearance is eliminated via the
CYP3A4, CYP1A2 and CYP2J2-dependent pathways and
intestinal excretion. Recommended dosage is twice daily for
dabigatran and apixaban and once daily for rivaroxaban.
Phase III studies
The Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) was a randomized trial designed to
compare two ﬁxed doses of dabigatran (110 mg per bid
and 150 mg per bid), each administered in a blinded manner,
with open-label use of VKA in patients who had AF and
were at an increased risk for stroke. The Rivaroxaban Once
Daily (20 mg) Oral Direct Factor Xa Inhibition Compared
with VKA for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation (ROCKET-AF) and the Apixaban (5 mg
per bid) for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) were multicenter,
randomized, double-blind, double-dummy, event-driven tri-
als. The three studies were designed as parallel group, non-
inferiority trials. NOA were considered non-inferior to
warfarin if they had at least half of the effect-size of
warfarin as compared with placebo. Based on a previously
published meta-analysis [6], a very similar non-inferiority
margin (D) was chosen (1.46 in the RELY and ROCKET
AF, 1.44 in the ARISTOTLE study). Primary analysis was
pre-speciﬁed to be performed in the per-protocol population
in the ROCKET trial. Results are encouraging enough to
predict a major shift in the treatment of these patients. In
this review, we give a comparison of these three trials in what
we think would be a guide to a critical evaluation and a
rational choice of NOA.
Inclusion criteria
All the studies included patients with EKG-documented non-
valvular AF. Patients with an EKG-documented atrial ﬂutter
were also included in ARISTOTLE study. At least one of the
risk factors for stroke among those comprised in CHADS2
score (congestive heart failure, hypertension, older than
75 years, diabetes, stroke/transient ischemic attack) was a
prerequisite for enrolment in the RELY and ARISTOTLE
trials. In contrast, ROCKET-AF enrolled only patients at a
moderateto high risk of a stroke (i.e. a CHADS2 score of 2 or
more).
Exclusion criteria
As shown in Table 2, there were numerous exclusion criteria
for entry in the RE-LY, ROCKET-AF and ARISTOTLE
studies. Among them, the Apixaban study excluded only
patients with an ischemic stroke within the previous 7 days,
whereas in both the Dabigatran and Rivaroxaban studies
patients were excluded if they had a disabling stroke within
the previous 6 months or any stroke within the previous
14 days. Fibrinolytic treatment was not an exclusion criterion
if used within 2 to 10 days before randomization in the
Dabigatran and Rivaroxaban studies, respectively. All the
studies excluded patients with a history of intracranial,
intraocular, spinal, retroperitoneal or traumatic intra-articu-
lar bleeding. Gastrointestinal bleeding in the previous year
and major surgery in the previous month were exclusion
criteria in the Dabigatran and Rivaroxaban studies. Recent
malignancy or radiation therapy and ulcer disease in the
previous 30 days were exclusion criteria in the Dabigatran
trial. Patients with severe renal impairment and those with
hemoglobin (Hb) < 10–9 g dL)1 or a platelet count of less
than 100 or 90 · 109 L)1 were excluded from all three trials.
Patients with planned cardioversion, major surgery or
invasive procedures were excluded in the Rivaroxaban study;
no information whatsoever was provided in the other two
trials. However, some recent data on successful cardioversion
on Dabigatran treatment do exist in literature [7]. The
concomitant use of dual anti-platelet agents was not allowed
in the Rivaroxaban and Apixaban studies; moreover, the
concomitant use of other drugs was not allowed in the
rivaroxaban study. Pregnancy and lactating patients were
excluded in all the studies. Finally, patients with liver disease
were excluded in the Dabigatran and Rivaroxaban studies.
Table 1 Characteristics of novel oral anticoagulants (4,5 modiﬁed)
Dabigatran Rivaroxaban Apixaban
Target IIa Xa Xa
Prodrug Yes No No
Hours to Cmax 2 2–4 1–3
Linear pharmacokinetics Yes No Yes
Bioavailability 7% 80% 66%
Protein binding 35% > 90% 87%
Half-life (h) 12–14 9–13 8–15
CYP metabolism No Yes (CYP3A4/A5, CYP2J2) Yes (CYP3A4, CYP1A2, CYP2J2)
Eﬄux transporter P-gp Yes Yes Yes
Renal elimination 80% 66% (33% cleared unchanged) 25%
Dosing Twice a day Once a day Twice a day
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Comments
Exclusions may leave future patients with similar characteris-
tics susceptible to unintended harm from an inappropriate
generalization of trial results. In the ARISTOTLE study there
were less stringent exclusion criteria as compared with the other
trials. Thus, it is possible that the Aristotle trial did not exclude
patients who may be more likely to represent the population
treated in clinical settings with a better relationship between
efﬁcacy and effectiveness.
Characteristics of randomized patients
The characteristics of randomized patients in the experimental
drug arm are described in Table 3. In contrast to the RE-LY
and ARISTOTLE studies, patients in the ROCKET-AF study
were at a higher risk of a stroke (mean CHADS2 score 3.48),
were older and with a previous stroke or systemic embolism in
more than 50% of cases. Moreover, diabetes and hypertension
were more frequent among the enrolled patients in the
ROCKET-AF study.
Comments
Interestingly, the mean body weight was high in all three trials
and this is in line with the hypothesis that obesity is a risk factor
for AF [8].
Primary end point
The primary efﬁcacy outcome was a stroke (ischemic or
hemorrhagic) or systemic embolism. The median duration of
Table 2 Exclusion criteria
Conditions Dabigatran Rivaroxaban Apixaban
Heart valve disorders Excluded Excluded Excluded
Disabling stroke within the previous 6 months or any stroke within the previous 14 days Excluded Excluded Not Excluded*
Increased risk of bleeding
Surgery within the previous month Excluded Excluded NR
History of intracranial, intraocular, spinal retroperitoneal or a traumatic
intra-articular bleeding
Excluded Excluded Excluded
Gastrointestinal hemorrhage within the past year Excluded Excluded NR
Ulcer disease in the previous 30 days Excluded NR NR
Recent malignancy or radiation therapy Excluded NR NR
Severe renal impairment: creatinine clearance less than 30 mL min)1 Excluded Excluded Excluded
Anemia (Hb < 10 g dL)1) or thrombocytopenia (< 100–90 · 109 L)1) Excluded Excluded Excluded
Planned cardioversion NR Excluded NR
Indication for anticoagulation other than AF Excluded Excluded Excluded
Major surgery or invasive procedure planned NR Excluded NR
Simultaneous treatment with both aspirin and a thienopyridine NR Excluded Excluded
Fibrinolytic treatment within 2–10 days Excluded Excluded NR
Liver disease Excluded Excluded NR
Pregnant and lactating patients Excluded Excluded Excluded
Concomitant therapies NR Excluded NR
NR, not reported; Hb, haemoglobin.
*Excluded only in the case of a very recent ischemic stroke (within 7 days).
Creatinine clearance less than 25 ml min)1.
Anticipated need for chronic treatment with a non-steroidal anti-inﬂammatory drug; Current or planned treatment with a strong inhibitor of
cytochrome P450 3A4, such as ketoconazole or protease inhibitors; Treatment with a strong inducer of cytochrome P450 3A4, such as rifampin/
rifampicin.
Table 3 Characteristics of randomized patients in tested groups*
Risk factors Dabigatran 110 mg
N = 6015
Dabigatran 150 mg
N = 6076
Rivaroxaban 20 mg
N = 7131
Apixaban 5 mg
N = 9120
Age (years) 71.4 ± 8.6 71.5 ± 8.8 73 (65–78) 70 (63–76)
Female gender (%) 35.7 35.8 39.7 35.5
Weight (Kg) 82.9 ± 19.9 82.5 ± 19.4 – 82 (70–96)
BMI, median (IQR) 28.3 (25.2–32.1)
Prior stroke or embolism (%) 19.9 20.3 54.9 19.2
Heart failure (%) 32.2 31.8 62.6 35.5
Diabetes (%) 23.1 23.4 40.4 25.0
Hypertension (%) 78.8 78.9 91.3 87.3
CHADS2 score (mean) 2.1 ± 1.1 2.2 ± 1.2 3.48 ± 0.94 2.1 ± 1.1
BMI, body mass index.
*Plus-minus values are means ± SD.
Values are expressed as median (IQR).
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the follow-upperiodwas2.0 years in theRELYstudy, 1.9 years
in the ROCKET-AF study and 1.8 years in the ARISTOTLE
study. Results for intention-to-treat population are shown in
Table 4. Overall, all NOA resulted in being non-inferior to
VKA in reducing stroke or systemic embolism in patients with
AF. Dabigatran 150 mg and apixaban were superior to VKA.
Among the patients in theVKAgroups, themeanpercentage of
time spent in the therapeutic range (TTR) was 64% in RELY,
55% in ROCKET-AF and 62.2% in the ARISTOTLE study.
Comments
Rivaroxaban fared better when investigators analyzed only
patients treated with the drug in an on-treatment superiority
comparison (P = 0.02); however, in an intention-to-treat
superiority analysis, rivaroxaban was not shown to be superior
to warfarin owing to events occurring when switching to VKA
at the end of the study. This might be related to the low half-life
of rivaroxaban, that when suspended left patients unprotected
against a stroke until VKA fully reached antithrombotic levels.
On the other hand, most patients assigned to the VKA arm,
had probably a therapeutic INR at the end of the study. We
can argue that, like dabigatran and apixaban, rivaroxaban also
did signiﬁcantly better than warfarin in intention-to-treat
analysis in the absence of this inconvenience. Notably, this
poses a warningwhen there is the need to switch rivaroxaban to
warfarin in clinical practice. Patients in the VKA arm of the
ROCKET study had their INR in a therapeutic interval in a
lower percentage of time: older high-risk patients were enrolled
in this study with the vast majority affected by heart failure, a
condition per se predisposing to a high INR variability.
The primary safety outcome
The primary safety outcome in the RE-LY and Aristotle
studies was major bleeding deﬁned according to the deﬁnition
proposed by the International Society on Thrombosis and
Haemostasis (ISTH) [9]. A composite of major and non-major
clinically relevant bleedings was considered as a primary
outcome in the ROCKET AF study [2]. A subcategory of
major bleeding termed as life-threatening bleeding was also set
in the RE-LY trial [1]. The rate of major bleedings in the
groups treated with VKA was rather consistent across the
studies, ranging from 3.09% per year to 3.4% per year. In the
Dabigatran vs. VKA study, major bleeding was signiﬁcantly
reduced (RR = 20%, P = 0.003) in the lower Dabigatran
dose group and life-threatening bleedings was less frequent
with both Dabigatran doses.
An important reduction of intracranial hemorrhages was
recorded with both Dabigatran doses, with a risk reduction of
60% or more. In contrast, a signiﬁcant increase in gastroin-
testinal bleeding was observed with the higher Dabigatran dose
vs. VKA (P < 0.001) (Table 5). In the ROCKET-AF study
no difference was detected for major and non-major clinically
relevant bleedings (primary safety outcome) between the
Rivaroxaban- and VKA-treated group; however, a signiﬁcant
increase in gastrointestinal bleeding and a signiﬁcant lower rate
of intracranial hemorrhages was recorded in the Rivaroxaban
group. A signiﬁcant reduction (P < 0.001) in both primary
and secondary safety outcomes was documented in Apixaban-
vs. VKA-treated subjects in the ARISTOTLE study. Particu-
larly important was the reduction in intracranial hemorrhages
(risk reduction > 50%).
Comments
Sub-analyzes focusing on speciﬁc aspects of the trial results
have recently been published. As far as age is concerned, the
risk of all major bleedings was lower with both doses of
Dabigatran vs. VKA in patients aged < 75 years; in those
aged ‡ 75 years both doses of Dabigatran fared better when
the risk of intracranial bleeding was considered, but extracra-
nial bleeding was similar or higher. [10]. The annual rates of
major and intracranial bleeding increased signiﬁcantly
(P < 0.001) among all participants in association with
increasing CHADS2 scores (from 0 to 1, 2, or 3 to 6); this
signiﬁcant increase was present for both experimental drug
doses for major bleeding and only for the higher dose for
intracranial bleeding [11].
Lower rates of total bleeding were reported from partici-
pating centers that had lower TTR levels of the VKA-treated
group; these results are attributed by the investigators to a
possible underdosing or poor compliance at sites with lower
TTR or more meticulous recording of bleedings at sites with
better TTR [12]. It is evident that more elderly patients were
present in the ROCKET-AF study and especially that this
study included more severe patients, as shown by the high
number of those with a CHADS2 ‡ 3, with a previous stroke or
transient ischemic attack and with concomitant aspirin use.
The importance of increasing age (especially ‡ 75 years) and a
Table 4 Primary outcome (intention-to-treat population)
No./100 patient-year Relative risk (95% CI) Noninferiority (P) Superiority (P)
Dabigatran 110 1.53 0.91 (0.74–1.11) < 0.001 0.34
Dabigatran 150 1.11 0.66 (0.53–0.82) < 0.001 < 0.001
Warfarin 1.69
Rivaroxaban 2.1 0.88 (0.75–1.03) < 0.001 0.12
Warfarin 2.4
Apixaban 1.27 0.79 (0.66–0.95) < 0.001 0.01
Warfarin 1.60
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high CHADS2 score (especially ‡ 3) on the risk of either
thrombotic or hemorrhagic complications in this patient setting
was recently conﬁrmed by two subgroup analyzes of the
RE-LY trial [10,11]. From a clinical point of view it would be
better to avoid dabigatran and rivaroxaban in patients with a
history of gastrointestinal disorders or patients taking antiplat-
elet drugs or the chronic use of non-steroid anti-inﬂammatory
drugs. Apixaban can be used in these patients while a
preference for rivaroxaban should be given in patients without
gastrointestinal disorders and a high CHADS2 score as they
were speciﬁcally tested in the ROCKET-AF trial.
Death from any cause
A reduction in mortality from any cause (Table 6) is noticeable
in all the three studies and it is signiﬁcant in the ARISTOTLE
trial. However, an absolute risk reduction is similar in all the
trials (0.38%; 0.49; 0.4; 0.42 for Dab 110, Dab 150, Rivarox-
aban and Apixaban, respectively) with around one death
avoided every 250 treated patients.
Side effects
No signiﬁcant alterations in liver enzymes (aspartate transam-
inase/alanine transaminase) were observed across different
studies. Dabigatran, but not Rivaroxaban or Apixaban, is
associated with a signiﬁcant increase in gastrointestinal disor-
ders. Dyspepsia, nausea, upper abdominal pain and diarrhoea
were the most common side effects reported during the 2 years
follow-up in the RE-LY trial, with both 150 mg and 110 mg
twice daily dosages as comparedwith VKA (11.8%, 11.3%and
5.8%, respectively); this brought a higher rate of drug discon-
tinuation (2.2%, 2.1% and 0.6%, respectively; P < 0.001) [1].
The presence of dyspepsia may depend on the increased acidity
as a result of tartaric acid in theDabigatran capsules. In theRE-
LY trial, a clinical myocardial infarction (MI) was signiﬁcantly
more frequent inDabigatran 150 mg twice daily comparedwith
VKA (0.74% vs. 0.53%; P = 0.048), showing a trend towards
signiﬁcance in Dabigatran 110 mg (0.72% vs. 0.53%;
P = 0.07) [1]. A subsequent analysis including four previously
unreported clinical MI and 28 silent MI concluded that there
was a non-signiﬁcant increase in MI with Dabigatran 150 mg
per bid compared with VKA [13]. Recently, a meta-analysis of
the seven trials comparing Dabigatran with VKA, enoxaparin
and placebo in different clinical settings showed an increased
relative risk (27–33%) of MI among all Dabigatran-treated
patients [14]. No statistical differences in side effects as
compared with VKA were demonstrated in the ROCKET-
AF and ARISTOTLE trials (published as supplementary
appendix of the original investigations).
Table 5 Bleeding complications recorded in the phase III clinical trials
Trial Safety outcomes (bleeding) % (years) Hazard ratio; P-value
RE-LY D 110 D150 W D 110 vs. W D 150 vs. W D 150 vs. D 100
Major 2.71 3.11 3.36 0.80; 0.003 0.93; ns 1.16; 0.052
Life threatening 1.22 1.45 1.80 0.68; < 0.001 0.81; 0.04 1.19;ns
Intracranial 0.23 0.30 0.74 0.31; < 0.001 0.40; < 0.001 1.32;ns
Gastrointestinal 1.12 1.51 1.02 1.10; ns 1.50; < 0.001 1.36; 0.007
Minor 13.16 14.84 16 0.79; < 0.001 0.61; 0.005 1.16;< 0.001
ROCKET R W R vs. W
AF Primary safety outcome 14.9 14.5 1.03; ns
Major 3.6 3.4 1.04; ns
Intracranial 0.5 0.7 0.67; 0.02
Gastrointestinal 3.1 2.2 1.46;< 0.001
Non-major clinically relevant 11.8 11.4 1.04; ns
ARISTOTLE A W Hazard ratio; P-value A vs. W
Primary (major) 2.13 3.09 0.69; < 0.001
Intracranial 0.33 0.80 0.42; < 0.001
Secondary (major and
non-major clinically
relevant)
4.07 6.01 0.68; < 0.001
vs., versus; D, dabigatran; R, rivaroxaban; A, apixaban; W, warfarin; Asp, aspirin; Cr, creatinine; CrCl, creatinine clearance; p-values are reported
for underlined results.
Table 6 Death from any cause across the studies
Clinical Events Study Drugs
% per year
Relative risk (95% CI) P-valueNOA W
Death from any cause RE-LY Dabigatran 110 3.75 4.13 0.91 (0.80–1.03) 0.13
Dabigatran 150 3.64 4.13 0.88 (0.77–1.00) 0.051
ROCKET-AF Rivaroxaban 4.5 4.9 0.92 (0.82–1.03) 0.15
ARISTOTELE Apixaban 3.52 3.94 0.89 (0.80–0.99) 0.047
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Comments
Before prescribing NOA, it might be appropriate to take into
account both speciﬁc drug side-effects and individual patient
characteristics. A clinical follow-up of patients taking dabig-
atran is mandatory to avoid drug discontinuation in relation to
gastrointestinal side-effects. As VKA are effective in the
secondary prevention of MI, they may be considered together
with the novel anti-Xa oral anticoagulants as a ﬁrst choice in
patients with a previous MI or known coronary artery disease
[14]. Post marketing monitoring will shed light over this issue.
Quality of the studies
Table 7 reports the study design, number of subjects lost to
follow-up and withdrawals in the published phase III studies
comparing NOA with VKA. All studies had adequate
randomization, provided by a computerized voice response
system. Contrary to the double-blind, double-dummy ARIS-
TOTLE and ROCKET trials, RE-LY had an open-label
design in which both patients and physicians were aware of the
investigational drug. This latter study is therefore slightly more
prone to observer bias, which may artiﬁcially increase the
efﬁcacy of a new treatment up to 17% higher [15,16].
All studies had a very limited and negligible number of
subjects lost to follow-up (0.11–0.48% of all enrolled subjects).
In all studies and in all treatment arms, there were signiﬁcant
numbers of subjects not completing the scheduled study
observation time. Across all studies, the mean proportion of
patients leaving the investigational treatment was 23.0% and
22.8% in patients on VKA (P = 0.63); however, the odds of
leaving treatment were signiﬁcantly different within each
treatment arm in each individual study. Only the RE-LY trial
fully reported the reasons for patient drop-out.
One of the clinically more relevant issues is subgroup
analysis, that is, however, prone to both type I and II errors.
First, all subgroup analyzes should be pre-speciﬁed to control
for multiple comparisons (ﬁshing effect). Second, subgroup
analysis should be done only for the adequate sub-sample size,
accounting for the expected low rate of events. For instance,
given an incidence of major endpoints around 1–2%per year, a
subgroup of less than a thousand individuals is expected to
have around 15 events, resulting in very imprecise estimates.
Both the ARISTOTLE and ROCKET trials, but not the
RE-LY, did pre-specify some subgroup analysis in the study
protocol. The ROCKET trial reported more subgroups
analyzes than those speciﬁed in the study protocol, sometimes
with an inadequate subgroup size.
Comments
The quality of evidence from the published phase III studies is
indisputably high, with a low number of withdrawals and
follow-up losses. However, the RE-LY trial had a lower Jadad
score because of its open-label design [17], and a possible
(although small) overestimate of a drug effect could not be
excluded for dabigatran.
Specific issues
Renal function
Renal impairment can inﬂuence the balance between the safety
and efﬁcacy of NOA. They have different renal elimination (see
Table 1) and this issue may affect the choice of a speciﬁc agent.
Dabigatran is almost exclusively eliminated by the kidney and
its pharmacokinetic properties are clearly affected by renal
failure. After oral administration of a single dose of 150 mg,
the areas under the plasma concentration-time curve (AUC)
were 3.2- and 6.3-fold higher in subjects with moderate
(creatinine clearance 30–50 mL min)1) and severe renal impair-
ment (creatinine clearance < 30 mL min)1), as compared
with the values in healthy subjects [18]. In subjects with severe
renal impairment, the mean terminal elimination half-life was
doubled (28 vs. 14 h for control) [18]. Thus, exposure to
Dabigatran is increased by renal impairment and correlates
with the severity of renal dysfunction. As a consequence, the
drug requires dose adjustment in patients with moderate renal
impairment and is contraindicated in those with severe renal
insufﬁciency [19,20]. These last patients were not included in
the phase III RE-LY study [1]. In spite of a dose reduction,
drug accumulation and overdose were reported in elderly
patients with a low body weight and moderate renal insufﬁ-
ciency leading to severe and fatal bleeding complications [21].
For patients with stage 4 Chronic Kidney Disease (creatinine
clearance < 30 mL min)1), dose adjustment to 75 mg twice
daily is recommended by the Food and Drug Administration
on the basis of pharmacokinetic and pharmacodynamic
considerations more than safety or efﬁcacy data [22]. However,
other regulatory boards, including the European Medicine
Agency, issued a recommendation on the 110 mg twice-daily
dose for use on an individual basis and at the physicians
Table 7 Study design, number of subjects lost to follow-up and withdrawals
Study design
Lost to
follow-up N (%)
Discontinuation % before end of study
Jadad
scaleNOA VKA P
Dabigatran 110 mg vs. warfarin Open-label 20 (0.11) 20.7 16.6 < 0.0001 3
Dabigatran 150 mg vs. warfarin Open-label 20 (0.11) 21.1 16.6 < 0.0001 3
Rivaroxaban vs. warfarin Double-blind 32 (0.22) 23.7 22.2 0.03 4
Apixaban vs. warfarin Double-blind 69 (0.48) 25.3 27.5 0.001 4
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discretion in patients with low thromboembolic and high
bleeding risks [23].
Rivaroxaban and Apixaban excretion is only partly depen-
dent on renal function (Table 1) and the risk of drug
accumulation in patients with renal insufﬁciency is lower than
that observed with Dabigatran. Both drugs can be adminis-
tered at ﬁxed doses in patients with moderate renal impairment
[24,25]. Importantly, severe renal disease was an exclusion
criterion from the trials comparing these drugs with VKA in
patients with AF [2,3].
Comments The following practical recommendations can
be given: (i) renal function should be evaluated in all patients
before choosing one of the NOA [19,20,25]; (ii) in patients with
moderate renal impairment (creatinine clearance 30–
50 mL min)1) Dabigatran should be given at a reduced dose
(110 mg per bid) and renal function monitored during
treatment every 6 months; Rivaroxaban, Apixaban or VKA
are probably safer options, particularly in elderly patients with
a low body weight [21]; (iii) in patients with severe renal
impairment (creatinine clearance < 30 mL min)1) NOA
should not be given.
Elderly patients
Patients aged ‡ 75 years were 40.1%, 43.1% and 31.2% in
RELY, ROCKET AF and ARISTOTLE, respectively. Data
analysis in age subgroups of the above-mentioned trials are
limited (Table 8). Data of the RE-LY trial were examined in
detail in relation to age; a highly signiﬁcant interaction between
age and major bleeding was found (see above) [10]. In the
ROCKET-AF study, the efﬁcacy and safety of rivaroxaban
appears to be consistent across ages, although, to our
knowledge, no detailed analysis on elderly people has emerged
so far. Apixaban was shown to be superior to VKA in the
ARISTOTLE trial and no interaction with age was reported
for the efﬁcacy outcome and major bleeding.
Comments The mean age of patients enrolled in the
published trials is lower than that reported in observational
studies performed in routine practice [26,27]. Renal function
declines with age and a creatinine clearance reduction of about
1 mL min)1 per year after the age of 40 years is estimated. It is
known that a large proportion of elderly AF patients have
severe or moderate renal impairment [28]. It was estimated that
a 97-year-old patient taking Dabigatran etexilate has an
approximately 11.5% increase in the plasma concentration-
time curve at the steady state as compared with a 72-years-old
patient [29]. Since the duration of anticoagulant treatment in
patients with AF is life long, the progressive decline in renal
function needs to be considered. Moreover, elderly patients are
more frequently prone to acute episodes of intercurrent
diseases, such as infections or heart failure, that are
commonly associated with a rapid worsening of the renal
function. This issue should be carefully evaluated in patients
treated with NOA, particularly Dabigatran that is mainly
cleared via the kidneys. The European Medicines Agency and
the Canadian Health Authority approved Dabigatran for the
prevention of stroke and systemic embolism in patients with
AF at the dose of 150 mg bid and at the dose of 110 mg bid for
elderly patients aged > 80 years and for patients at a higher
risk for bleeding.
Conclusion
The large Phase III clinical trials of NOAs in the prevention
of stroke and peripheral embolism in patients with AF
showed that they are not inferior to warfarin and even
superior (dabigatran 150 mg bid and apixaban 5 mg bid).
This does not mean that all NOAs are equivalent as the
choice of the new drug depends on many other consider-
ations. In Table 9 we list the strengths and weakness of
NOAs that could help in choosing a speciﬁc drug. For
instance, in a 66 years of age hypertensive patient with
normal renal function and a low risk of bleeding, dabigatran
150 mg bid or apixaban may be chosen as in phase III trials
both signiﬁcantly reduced the primary efﬁcacy end point as
compared with warfarin. In a similar patient with moderate
renal insufﬁciency (creatinine clearance 30–50 mL min)1) or
an increased risk of bleeding dabigatran 110 mg bid or
apixaban 5 mg bid could be the choice. In high-risk elderly
patients with a previous stroke or congestive heart failure or
recent acute coronary syndrome, rivaroxaban might be
preferred as it was used in this clinical setting and it was
recently shown to reduce major cardiovascular events in the
ATLAS ACS 2- TIMI 51 study [30]. Moreover, rivaroxaban
may be considered in patients with expected poor compliance
as it is administered once daily. On the other hand, in
Table 8 Eﬃcacy and safety outcome (expressed as rate % per years) in patients aged ‡ 75 years in the trials with the new oral anticoagulants compared
with warfarin
Tested drug
Eﬃcacy outcome
(% per year)
Tested drug
Eﬃcacy outcome
(% per year)
warfarin
Safety outcome
(% per year)
Tested drug
Safety outcome
(% per year)
warfarin
RE-LY Dabigatran 110 mg bid 1.89 2.14 4.43 4.37
Dabigatran 150 mg bid 1.43 2.14 5.10 4.37
ROCKET AF Rivaroxaban 2.67 4.03 25.78* 23.43*
ARISTOTLE Apixaban 1.6 2.2 3.3 5.2
*Major and clinically relevant non major bleeding.
Novel anticoagulants in atrial ﬁbrillation 1985
 2012 International Society on Thrombosis and Haemostasis
patients on multiple medications, dabigatran might be
considered in light of its less drug interactions (no cyto-
chrome metabolism). In patients with previous gastrointesti-
nal bleeding or dyspepsia, apixaban should be considered as
the ﬁrst choice. In very elderly patients with declining renal
function either apixaban or rivaroxaban may be preferred or
warfarin in case of severe renal insufﬁciency. These are just
examples; however, further research to enhance our knowl-
edge on the new drugs is mandatory. In this respect, the
extension of the RE-LY study (RELY-ABLE trial [32]) will
give us more information on the long-term safety of this new
agent.
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